食管癌质子束放疗的剂量学与急性毒性:REG001-09 试验结果
基于质子协作组 REG001-09 登记研究,分析 2010–2019 年 10 家机构 155 例接受质子放疗的食管癌患者。中位剂量 50.51 GyE,≥3 级毒性 14%,最常见为吞咽困难(6%)、食管炎(4%)、厌食(4%)和恶心(2%),无 4 级淋巴细胞减少及 5 级毒性。心脏、肺、肝脏平均剂量及脊髓最大剂量分别为 10.0、4.8、3.8 和 34.2 GyE。
要点
- 质子放疗食管癌 ≥3 级毒性 14%,最常见吞咽困难 6%、食管炎 4%、厌食 4%。
- 心脏、肺、肝脏平均剂量分别为 10.0、4.8、3.8 GyE,脊髓最大剂量 34.2 GyE。
核心结论
- 质子束放疗在根治性食管癌治疗中提供优异的剂量学参数和低毒性。
研究设计与样本
- 基于质子协作组 REG001-09 登记研究,纳入 2010–2019 年 10 家机构 155 例接受质子放疗的食管癌患者,汇总人口学、临床病理、毒性和剂量学信息。
主要发现
- 中位剂量 50.51 GyE(范围 41.4–70.1),≥3 级毒性 22 例(14%),最常见为吞咽困难(6%)、食管炎(4%)、厌食(4%)和恶心(2%)。
- 无 4 级淋巴细胞减少事件,无 5 级毒性。
- 心脏、肺、肝脏平均剂量及脊髓平均最大剂量分别为 10.0 GyE、4.8 GyE、3.8 GyE 和 34.2 GyE。
- 胃食管交界处肿瘤患者中 8% 发生急性 ≥3 级毒性,心脏、肝脏、右肾和左肾平均剂量分别为 10.5 GyE、3.9 GyE、0.4 GyE 和 4.9 GyE。
临床怎么用
- 质子束放疗可作为根治性食管癌的治疗选择,其剂量学参数优异且急性 ≥3 级毒性发生率低。
局限性
- 本文为登记研究,非随机对照,比较效益尚待正在进行的前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Concurrent chemoradiation plays an integral role in the treatment of esophageal cancer. Proton beam radiation therapy has the potential to spare adjacent critical organs, improving toxicity profiles and potentially improving clinical outcomes. METHODS AND MATERIALS: We evaluated the REG001-09 registry for patients undergoing proton radiation therapy for esophageal cancer. Demographic, clinicopathologic, toxicity, and dosimetry information were compiled. RESULTS: We identified 155 patients treated at 10 institutions between 2010 and 2019. One hundred twenty (77%) had adenocarcinoma and 34 (22%) had squamous cell carcinoma. One hundred thirty-seven (88%) received concurrent chemotherapy. The median delivered dose was 50.51 Gy-equivalent (GyE; range, 41.4-70.1). Grade ≥3 toxicities occurred in 22 (14%) of patients and were most commonly dysphagia (6%), esophagitis (4%), anorexia (4%), and nausea (2%). There were no episodes of grade ≥4 lymphopenia and no grade 5 toxicities. The average mean heart, lung, and liver doses and average maximum spinal cord dose were 10.0 GyE, 4.8 GyE, 3.8 GyE, and 34.2 GyE, respectively. For gastroesophageal junction tumors, 8% of patients developed acute grade ≥3 toxicity and the mean heart, liver, right kidney, and left kidney doses were 10.5 GyE, 3.9 GyE, 0.4 GyE, and 4.9 GyE, respectively. Gastroesophageal junction location was protective against development of grade ≥3 toxicity on univariate (P = .0009) and multivariate (P = .004) analysis. CONCLUSIONS: Proton beam radiation therapy affords excellent dosimetric parameters and low toxicity in patients with esophageal cancer treated with curative intent. Prospective trials are underway investigating the comparative benefit of proton-based therapy.
引用
- Parzen JS, Chuong MD, Chang J, et al. Dosimetry and Acute Toxicity Profile of Patients With Esophageal Cancer Treated With Proton Beam Radiation Therapy: Outcomes From the Proton Collaborative Group REG001-09 Trial. Adv Radiat Oncol. 2021. PMID: 34646969. doi:10.1016/j.adro.2021.100751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。